Get the Stockscreener App
4.24
0.24%
-0.010
After Hours:
4.35
0.11
+2.59%
Coya Therapeutics Inc stock is traded at $4.24, with a volume of 74,538.
It is down -0.24% in the last 24 hours and up +4.69% over the past month.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells (Tregs). The company's initial development programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases with high unmet medical needs.
See More
Previous Close:
$4.25
Open:
$4.27
24h Volume:
74,538
Relative Volume:
0.54
Market Cap:
$99.46M
Revenue:
$7.95M
Net Income/Loss:
$-21.23M
P/E Ratio:
-3.5319
EPS:
-1.2005
Net Cash Flow:
$-11.90M
1W Performance:
+4.18%
1M Performance:
+4.69%
6M Performance:
-26.39%
1Y Performance:
-27.02%
1-Day Range:
$4.17
$4.365
1-Week Range:
$4.08
$4.365
52-Week Range:
$3.7101
$7.75
Coya Therapeutics Inc Stock (COYA) Company Profile
Name
Coya Therapeutics Inc
Sector
Industry
Phone
650.739.3939
Address
12645 MEMORIAL DR., SUITE F1 #305, HOUSTON
Compare COYA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
COYA
Coya Therapeutics Inc
|
4.24 | 99.69M | 7.95M | -21.23M | -11.90M | -1.2005 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Coya Therapeutics Inc Stock (COYA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-09-25 | Initiated | Lake Street | Buy |
| Dec-04-24 | Initiated | D. Boral Capital | Buy |
Coya Therapeutics Inc Stock (COYA) Latest News
ALS Researchers Use Stratification, Diverse Endpoints To Address Heterogeneity - Clinical Leader
Coya Therapeutics raises $11.1M in private placement led by Dr. Reddy's - MSN
Analysts Offer Insights on Healthcare Companies: Monopar Therapeutics Inc (MNPR), ClearPoint Neuro (CLPT) and CG Oncology, Inc. (CGON) - The Globe and Mail
Coya Therapeutics, Inc. (NASDAQ:COYA) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Coya Therapeutics (NASDAQ:COYA) Upgraded to "Hold" at Wall Street Zen - MarketBeat
Mark H Pavao Net Worth (2026) - GuruFocus
COYA Options Volatility — NASDAQ:COYA - TradingView
COYA Options Chain — NASDAQ:COYA - TradingView
Is Coya (COYA) Stock Safe to Buy Now | COYA Q4 Earnings: Misses Estimates by $0.06Stability Report - Newser
COYA PE Ratio & Valuation, Is COYA Overvalued - Intellectia AI
COYA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Volume Report: Is Coya Therapeutics Inc impacted by rising ratesTrade Analysis Report & High Accuracy Trade Alerts - baoquankhu1.vn
Coya Therapeutics Is Maintained at Buy by D. Boral Capital - Moomoo
Coya Therapeutics' (COYA) Buy Rating Reiterated at D. Boral Capital - MarketBeat
Market Review: Is Coya Therapeutics Inc benefiting from innovation trends2026 Catalysts & Accurate Entry/Exit Alerts - baoquankhu1.vn
Coya Therapeutics (COYA) director receives 10,000 stock options at $4.53 - Stock Titan
New Coya Therapeutics (COYA) director Mark H. Pavao files initial Form 3 - Stock Titan
Stop Loss: Will Coya Therapeutics Inc outperform its industry peers2026 Bull vs Bear & Technical Pattern Based Signals - baoquankhu1.vn
Market Leaders: How do insiders feel about Coya Therapeutics Inc2026 Earnings Impact & Free High Return Stock Watch Alerts - baoquankhu1.vn
Coya Therapeutics Announces Publication Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting the Mechanistic Rationale for COYA 302 in Patients with ALS - Business Wire
Coya Therapeutics Announces Leadership Changes and New Director - The Globe and Mail
Coya Therapeutics founder steps down, adds new director By Investing.com - Investing.com Australia
Coya Therapeutics Announces Planned Board Transition and Appointment of Mark H. Pavao as Independent - PharmiWeb.com
Coya Therapeutics Announces Planned Board Transition and Appointment of Mark H. Pavao as Independent Director - BioSpace
COYA: Treg-focused therapies show promise in neurodegeneration, with pivotal trials underway - TradingView — Track All Markets
Investor Presentation (04/02/2026 00: 00 - marketscreener.com
Founder steps down as Coya Therapeutics (COYA) adds independent director Mark Pavao - Stock Titan
Coya Therapeutics founder steps down, adds new director - Investing.com
Monopar Therapeutics Inc (MNPR) Receives a Buy from Lake Street - The Globe and Mail
Portfolio Update: Is Coya Therapeutics Inc forming higher highs and higher lows2026 Market Mood & Reliable Intraday Trade Plans - baoquankhu1.vn
Death Cross: How do insiders feel about Coya Therapeutics IncExit Point & Daily Profit Focused Screening - baoquankhu1.vn
Brokerages Set Coya Therapeutics, Inc. (NASDAQ:COYA) PT at $16.00 - Defense World
Aug Sentiment: Is Coya Therapeutics Inc forming higher highs and higher lows2026 Retail Activity & Technical Buy Zone Confirmation - baoquankhu1.vn
D. Boral Capital Maintains Coya Therapeutics (COYA) Buy Recommendation - MSN
Analysts Are Bullish on Top Healthcare Stocks: NRX Pharmaceuticals (NRXP), Rezolute (RZLT) - The Globe and Mail
BTIG Reiterates Coya Therapeutics (COYA) Buy Recommendation - MSN
HC Wainwright Analysts Decrease Earnings Estimates for COYA - marketbeat.com
What is HC Wainwright’s Estimate for COYA Q1 Earnings? - Defense World
Sell Signal: How much upside does Coya Therapeutics Inc have2026 Big Picture & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Coya Therapeutics (NASDAQ:COYA) Given “Buy” Rating at HC Wainwright - Defense World
ReAlta Life Sciences Appoints Howard Berman, Ph.D., as CEO and Kia Motesharei, Ph.D., as President a - pharmiweb.com
What is HC Wainwright's Estimate for COYA Q1 Earnings? - MarketBeat
Coya Therapeutics, Inc. (NASDAQ:COYA) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
ReAlta Life Sciences Appoints Howard Berman, Ph.D., as CEO and Kia Motesharei, Ph.D., as President and COO - BioSpace
Coya Therapeutics' (COYA) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Coya Therapeutics: Advancing Treg-Focused Pipeline with Near-Term Catalysts in ALS and FTD Supporting Buy Rating - TipRanks
Coya Therapeutics (COYA) Analyst Rating Reiterated at 'Buy' by H - GuruFocus
[EFFECT] Coya Therapeutics, In... | COYA SEC FilingForm EFFECT - Stock Titan
ALDX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Coya Therapeutics (NASDAQ:COYA) Downgraded to Sell Rating by Wall Street Zen - MarketBeat
CEO Moves: Can Coya Therapeutics Inc sustain earnings growthInflation Watch & Community Consensus Trade Alerts - baoquankhu1.vn
Coya Therapeutics Inc Stock (COYA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.77%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):